Thought Leadership

Biomarkers of Chronic Kidney Disease: How ACR, GFR and Cystatin C Work Together in Screening, Diagnosis and Monitoring of Disease

  • Credit:1.0 ACCENT
  • Duration: 1 hr
  • Date:MAY.5.2016 1:00 PM - 02:00 PM

Price: $0.00

Member Price: $0.00

Rating: Member Average

DESCRIPTION

Risk assessment models have identified that nearly two-thirds of U.S. adults over the age of 20 are at risk of developing CKD at some point in their life. Within that population, specific high-risk groups have emerged such as diabetics, hypertensives, and those with a family history of chronic disease.

Screening of high risk individuals, along with subsequent confirmation of diagnosis and monitoring of the diagnosed, can be accomplished in a structured, financially feasible plan with the right biomarkers being utilized at the correct time in the continuum of disease.

Robert ChristensonSPEAKER

Robert H. Christenson, PhD, DABCC, FACB
Professor of Pathology and Professor of Medical and Research Technology
University of Maryland School of Medicine



More Information

Program

  • Importance of education (for both patients and medical professionals) on the risk of CKD, especially in light of the ease of POC urine-strip ACR testing and the ability of this test to rule out disease.
  • Diagnosis using a combination of ACR and GFR is an accurate way to diagnose CKD with strong positive predictive values.
  • GFR is essential in detecting and managing CKD, but is difficult to measure directly and is usually estimated. The KDIGO guideline recommends use of a cystatin C–based estimated glomerular filtration rate (eGFR) to confirm creatinine-based eGFR calculations within a certain range, while other studies support considering the type of patient being treated and the indication for testing before choosing a definitive method to calculate GFR.
  • Alternative ways to determine eGFR
  • Determining eGFR in special clinical settings (e.g. dialysis, pediatric and transplant patients).

Target Audience

Laboratory administrators, directors, and managers; pathologists; critical care physicians, and anyone involved in the diagnosis and management of patients with chronic kidney disease.

Supported By

siemens logo

AACC thanks Siemens Healthineers for their support of the 2016 Thought Leadership program and their commitment to the clinical laboratory community.